Home › Compare › TDBOF vs ABBV
TDBOF yields 2.52% · ABBV yields 3.09%● Live data
📍 TDBOF pulled ahead of the other in Year 7
Combined, TDBOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TDBOF + ABBV for your $10,000?
Toyota Boshoku Corporation manufactures and sells automotive interior systems and products, automotive filter and power train equipment components, automotive components, and fabric goods in Japan, the United States, rest of Asia, Oceania, China, Europe, and Africa. The company offers automobile and aircraft seats, and door trims; headliners, such as molded headliners for a panorama roof, overhead console illumination, and grab handles; and floor carpets, package trays, tonneau covers, and deck boards, as well as exterior components consisting of bumpers, fender liners, and engine undercovers. It also provides filter products, including air and oil filters; and anti-allergen and deodorizing, dust and pollen removal, and anti-bacterial cabins, as well as clean air filters. In addition, the company offers air induction part products, such as air induction systems and cleaners, intake manifolds, oil mist separators, timing chain covers, and cylinder head covers; and fuel cell part products comprising air filter for fuel cell vehicles, ion exchangers, and separators, as well as anti-droplet partition and weets. Further, it provides aircraft and railway seats; and textile components comprising seat fabrics, curtain-shield airbags, and seatbelt webbings. The company was founded in 1918 and is based in Kariya, Japan.
Full TDBOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.